SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001640334-22-000622
Filing Date
2022-03-30
Accepted
2022-03-30 17:16:47
Documents
108
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 20-F nymox_20f.htm   iXBRL 20-F 1630529
2 CERTIFICATION nymox_ex12a.htm EX-12.A 11674
3 CERTIFICATION nymox_ex12b.htm EX-12.B 10478
4 CERTIFICATION nymox_ex13a.htm EX-13.A 3474
5 CERTIFICATION nymox_ex13b.htm EX-13.B 3440
  Complete submission text file 0001640334-22-000622.txt   6358096

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA nymox-20211231.xsd EX-101.SCH 105841
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20211231_lab.xml EX-101.LAB 328461
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20211231_cal.xml EX-101.CAL 51431
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20211231_pre.xml EX-101.PRE 288491
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20211231_def.xml EX-101.DEF 166161
102 EXTRACTED XBRL INSTANCE DOCUMENT nymox_20f_htm.xml XML 1139465
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 22787686
SIC: 2835 In Vitro & In Vivo Diagnostic Substances